(Q34971191)

5 August 2017

title

Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening (English)

1 reference

prostate cancer screening

5 August 2017

main subject

cost–benefit analysis

1 reference

1 reference

1 reference

5

Alan W Partin

1 reference

5 August 2017

Lars Ellison

1

1 reference

5 August 2017

Carol D Cheli

series ordinal

2

1 reference

5 August 2017

Steven Bright

series ordinal

3

1 reference

5 August 2017

Robert W Veltri

series ordinal

4

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

60

1 reference

5 August 2017

issue

4 Suppl 1

1 reference

5 August 2017

page(s)

42-46

1 reference

Prostate-specific antigen

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901694-1

7 January 2021

ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901694-1

7 January 2021

Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901694-1

7 January 2021

Systematic overview of cost-utility assessments in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901694-1

7 January 2021

Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901694-1

7 January 2021

Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901694-1

7 January 2021

Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901694-1

7 January 2021

Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901694-1

7 January 2021

10.1016/S0090-4295(02)01694-1

Identifiers

DOI

1 reference

5 August 2017

1 reference